As an instance, Ference et al. used MR to analyze the impact of LDL-C reduction on the CAD risk caused by variants in NPC1L1 (ezetimibe target), HMGCR (statins target), or both (combinational treatment with ezetimibe and a statin) [64]. The gene discussed is NPC1L1; the disease is coronary artery disorder.